Drug intelligence / Profile preview

tavo-103

Development stage: Unknown
Lead developer: Tavotek Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Tavo-103 is a human monoclonal antibody targeting interleukin-1 beta (IL-1β), developed for the treatment of chronic inflammation. It is based on Tavotek Biotherapeutics' TavoPrecise antibody platform and is administered intravenously. The drug has completed dosing in Phase 1 clinical trials, with data suggesting an extended half-life compared to other IL-1β antibodies. Its mechanism of action involves modulation of IL-1β, a key cytokine involved in inflammatory processes[2][3][1].

Targets

IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on tavo-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tavo-103.

Explore the full profile